Keyword: Syndax Pharmaceuticals
Syndax’s shares slid after an ASCO abstract revealed lackluster data with entinostat, but it's forging ahead with a new combination study with Nektar.
Syndax’s entinostat-Keytruda combination may have posted small gains in NSCLC, but an enrichment biomarker could predict increased clinical benefit.
Syndax is set to put its cocktail through a phase 1b solid tumor trial ahead of midphase trials to demonstrate its safety and efficacy.
The new agreement clears the Roche subsidiary to test its Tecentriq in combination with Syndax’s entinostat in a subset of breast cancer patients.